Chromatin/Epigenetics

Epigenetics
Epigenetics means above genetics. It determines how much and whether a gene is expressed without changing DNA sequences. Epigenetic regulations include, 1. DNA methylation: the addition of methyl group to DNA, converting cytosine to 5-methylcytosine, mostly at CpG sites; 2. Histone modifications: posttranslational modificationEpigeneticss of histone proteins including acetylation, methylation, ubiquitylation, phosphorylation and sumoylation; 3. miRNAs: non-coding microRNA downregulating gene expression; 4. Prions: infectious proteins viewed as epigenetic agents capable of inducing a phenotype without changing the genome.
Products for Chromatin/Epigenetics
- Bromodomain(41)
- Aurora Kinase(48)
- DNA Methyltransferase(26)
- HDAC(124)
- Histone Acetyltransferases(48)
- Histone Demethylases(69)
- Histone Methyltransferase(120)
- HIF(60)
- JAK(109)
- MBT Domains(1)
- PARP(65)
- Pim(28)
- Protein Ser/Thr Phosphatases(34)
- RNA Polymerase(7)
- Sirtuin(53)
- Sphingosine Kinase-2(1)
- Polycomb repressive complex(2)
- SUMOylation(2)
- PAD(1)
- Epigenetic Reader Domain(139)
- MicroRNA(6)
- Protein Arginine Deiminase(7)
- Cat.No. Product Name Information
-
GC31365
γ-Oryzanol
γ-Oryzanol有效抑制小鼠纹状体中的DNA甲基转移酶(DNMTs)。抑制DNMT1和DNMT3a,IC50分别为3.2μM和22.3μM。
-
GC34958
(+)-JQ1 PA
(+)-JQ1 PA 是溴结构域和额外末端结构域 (BET) 抑制剂 JQ1 的衍生物,其 IC50 值为 10.4 nM。
-
GC13822
(-)-JQ1
BET bromodomain inhibitor
-
GC34964
(1S,3R,5R)-PIM447 dihydrochloride
(1S,3R,5R)-PIM447 (dihydrochloride)是PIM的抑制剂,来自专利US 20100056576 A1化合物实例72。对Pim1,Pim2和Pim3的IC50分别为0.095,0.522和0.369 μM。
-
GC34971
(3R,4S)-Tofacitinib
Tofacitinib(CP-690550)是高效JAK3抑制剂,IC50为1 nM,比对JAK2和JAK1的抑制性高20倍和100倍。
-
GC34972
(3S,4R)-Tofacitinib
Tofacitinib(CP-690550)是高效JAK3抑制剂,IC50为1 nM,比对JAK2和JAK1的抑制性高20倍和100倍。
-
GC34973
(3S,4S)-Tofacitinib
Tofacitinib(CP-690550)是高效JAK3抑制剂,IC50为1 nM,比对JAK2和JAK1的抑制性高20倍和100倍。
-
GC15104
(R)-(+)-Etomoxir sodium salt
carnitine palmitoyltransferase I (CPT1) inhibitor
-
GC34443
(R)-BAY1238097
(R)-BAY1238097是BAY1238097的低活性R型异构体。BAY1238097是一种有效的、BET与组蛋白结合的选择性抑制剂,通过下调c-Myc水平及下游转录组,在AML(急性髓性白血病)和MM(多发性骨髓瘤)模型中表现出较强的抗增殖活性。
-
GC11340
(R)-PFI 2 hydrochloride
SETD7 histone lysine methyltransferase inhibitor
-
GC34446
(rac)-BAY1238097
(rac)-BAY1238097是一种BET抑制剂,对BRD4的IC50值为1.02μM。用于癌症研究。
-
GC33198
(S)-JQ-35 (TEN-010)
(S)-JQ-35(TEN-010)是BET家族的抑制剂,有着潜在的抗肿瘤活性。
-
GC13634
(S)-PFI-2 (hydrochloride)
Negative control of (R)-PFI 2 hydrochloride
-
GC17055
1,2,3,4,5,6-Hexabromocyclohexane
JAK2 tyrosine kinase inhibitor
-
GC12775
2',3',5'-triacetyl-5-Azacytidine
prodrug form of 5-azacytidine, a DNA methyltransferase inhibitor
-
GC11873
2,4-Pyridinedicarboxylic Acid
Histone LSD inhibitor
-
GC10408
2-D08
Sumoylation inhibitor
-
GC11249
2-hexyl-4-Pentynoic Acid
Potent and robust HDACs inhibitor
-
GC15084
2-Methoxyestradiol (2-MeOE2)
Apoptotic, antiproliferative and antiangiogenic agent
-
GC14282
3-acetyl-11-keto-β-Boswellic Acid
5-lipoxygenase inhibitor